PhIIIMirvetuximabSoravtansineCombW/BevacizumabVSBevacizumab PaW/FrA+After2ndLine PlatinumChemo +Bev

Cancer
Krishnansu Tewari
Randomized, Multicenter, Open-label, Phase III Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FrA-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
Cervix
Corpus Uteri
Other Female Genital
Ovary

Study Description

Randomized, multicenter, open-label, Phase 3 study of mirvetuximab

soravtansine in combination with bevacizumab versus bevacizumab

alone as maintenance therapy for patients with FRα-high recurrent

platinum-sensitive epithelial ovarian, fallopian tube, or primary

peritoneal cancers who have not progressed after second-line platinumbased

chemotherapy plus bevacizumab (GLORIOSA)

Eligibility

  • Patients must be <18 years of age.
  • Patients must have an Eastern Cooperative Oncology Group performance status of 0 or 1.
  • Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian, primary

peritoneal, or fallopian tube cancer

  • Patients with PD while on or following platinum-based triplet therapy
  • Patients with prior wide-field radiotherapy affecting at least 20% of the bone marrow
  • Patients with > Grade 1 peripheral neuropathy per Common Terminology Criteria for

Adverse Events (CTCAE)

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.